Everything below concerns GRF(1-29). We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | Built on a 29 residue sequence |
| Primary target | GHRH receptor (GHRHR) | Class B G protein coupled receptor |
| Unconjugated half life | Minutes | Limited by protease degradation |
| Key modification | Four residue substitutions | Positions 2, 8, 15 and 27 |
| Common synonym | Modified GRF(1-29) | Usually denotes the form without DAC |
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
==== Saline breast prosthesis ==== The first commercial model of a breast prosthesis filled with saline solution was made by Laboratoires Arion of France, which they publicly presented as a prosthetic medical device in 1964. The modern models of prosthetic breasts filled saline-solution are made with vulcanized shells composed of a silicone elastomer of great elasticity, like that of the skin and tissues of a woman's breast. In an augmentation mammoplasty to emplace a saline breast-prosthesis, the plastic surgeon employs a short incision to the chest wall, through that incision the surgeon then inserts the collapsed, empty prosthetic breast into the breast-implant socket, then fills the implanted breast prosthesis with saline solution. The surgeon then contours the implanted prosthetic breast for anatomical symmetry, and afterwards sutures shut the insertion incision. Functionally, the implantation of a saline breast-prosthesis yields good-to-excellent results of increased breast-size, a smoother contour for the breast hemisphere, and anatomic symmetry; however, such a breast augmentation might ripple and wrinkle the skin envelope of the breast, cosmetic defects that make noticeable the presence of the prosthetic breast to the eye and to the touch. Such cosmetic defects of the breast surgery usually occur among women with a small volume of adipose tissue in their breast hemispheres.
== Factors influencing nutritional requirements == Differing conditions and objectives suggest the need for athletes to ensure that their sports nutritional approach is appropriate for their situation. Factors that may affect an athlete's nutritional needs include type of activity (aerobic vs. anaerobic), gender, weight, height, body mass index, workout or activity stage (pre-workout, intro-workout, recovery), and time of day. A nutritious diet will mitigate disturbances in performance. The key to a proper diet is a variety of foods, obtaining a balance of macronutrients, vitamins, and minerals.
== Use and effects == In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists DOPR's dose as 2.5 to 5 mg orally and its duration as 20 to 30 hours. It is said to have a very slow onset. The effects of DOPR have been reported to include closed-eye imagery, visuals, thinking changes, and insomnia and sleep disruption, among others. In one of the reports, it was described as a "heavy duty psychedelic", including strong and unignorable visuals.
== Prognosis == The median survival in idiopathic pulmonary fibrosis is 3–3.5 years. However, prognosis varies widely depending on the specific type and cause of ILD; some inflammatory forms may stabilize or improve with treatment. ILD is associated with a 3-fold increased risk of lung cancer. Life expectancy after lung transplant is 5.2 years in those with idiopathic interstitial pneumonias (including idiopathic pulmonary fibrosis) and 6.7 years in those with other types of ILD.
=== Pharmacokinetics === Microsome studies indicate zolpidem is metabolized by CYP3A4 (61%) CYP2C9 (22%), CYP1A2 (14%), CYP2D6 (<3%), and CYP2C19 (<3%). Less than 1% is excreted in urine unchanged. It is principally metabolized into three metabolites, none of which are believed to be pharmacologically active. The absolute bioavailability of zolpidem is about 70%. The drug reaches peak concentration in about 2 hours and has a half-life in healthy adults of about 2–3 hours. Zolpidem's half life is decreased in children and increased in the elderly and people with liver issues. While some studies show men metabolize zolpidem faster than women (possibly due to testosterone), others do not. A review found only a 33% lower clearance in women compared to men, suggesting the FDA's dosage reduction of 50% for women may have been too large.
Sources: en.wikipedia.org
==== Gastronomy ==== In gastronomy, in situ refers to the art of cooking with the different resources that are available at the site of the event. Here a person is not going to the restaurant, but the restaurant comes to the person's home.
== Desalting and Buffer Exchange vs. Dialysis == Dialysis is useful for many of the same desalting and buffer exchange applications performed with gel filtration chromatography, as both methods are based on similar molecular weight cut-off limits. Gel filtration has the advantage of speed (a few minutes vs. hours for dialysis) along with the ability to remove contaminants from relatively small-volume samples compared to dialysis which is an important feature when working with toxic or radioactive substances. Dialysis, on the other hand, is much less dependent on sample size as related to device format. For dialysis applications, achieving a high percentage sample recovery and molecule removal is generally straight forward with little optimization. For gel filtration applications it is important to select a column size and format that is suitable for your sample.
The relationship between the Druze and Christians in Israel has generally been marked by harmony and peaceful coexistence, with both communities living together in peace, harmony, and friendship. However, there have been rare clashes, including instances of violence by the Druze against Christians, such as the incident in 2005 in the town of town of Maghar. Druze and Christians in Israel participate in each other's cultural events, including births, weddings, funerals, and celebrations like the Christian festival of Mar Ilyas (Saint Elias) in Haifa. Additionally, many Druze students are enrolled in Christian schools across the Galilee and Haifa regions. Some Druze towns are situated near significant Christian holy sites, with the most prominent being the Catholic Muhraqa Monastery located 2 kilometres southeast of Daliyat al-Karmel, the largest Druze town in Israel, and marks the contest between prophet Elijah and the priests of Ba'al. It belongs to the Carmelite Order. In the predominantly Druze town of Hurfeish, there is the Church and House of Saint Mariam Baouardy. Interaction between Christians, including members of the Maronite, Eastern Orthodox, Melkite, and other churches, and the Unitarian Druze has resulted in the establishment of mixed villages and towns in Galilee region, Mount Carmel, and the Israeli-occupied portion of the Golan Heights. These include Abu Snan, Daliyat al-Karmel, Ein Qiniyye, Hurfeish, Isfiya, Kafr Yasif, Kisra-Sumei, Majdal Shams, Maghar, Peki'in, Rameh and Shefa-Amr, where more than 82,000 Druze and 30,000 Christians reside together.
== Cause == Buried bumper syndrome occurs when this internal bumper erodes into the wall of the stomach, sometimes becoming entirely buried within the wall of the stomach. Buried bumper syndrome tends to be a late complication of gastrostomy tube placement, but can rarely occur as early as 1 to 3 weeks after tube placement. Most cases occur more than 1 year after initial placement of the PEG tube. Excessive tightening of the external bumper is the primary risk factor for buried bumper syndrome. Maintaining the external bumper in a loose position may help prevent buried bumper syndrome. Additional risk factors include obesity, medications, poor wound healing, malnutrition, etc. Feeding tubes with soft balloon internal bumpers are less likely to cause buried bumper syndrome, compared with more firm or stiff polyurethane internal bumpers.
Sources: en.wikipedia.org
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.
DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.
No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.